Management of patients with multidrug-resistant tuberculosis

Area of Science:

• Public Health
• Infectious Diseases
• Pharmacology

Background:

• Multidrug-resistant tuberculosis (MDR-TB) poses a significant global health and economic challenge.
• Current MDR-TB treatment outcomes are poor, with high costs, prolonged treatment duration, and frequent adverse events.
• Increasing resistance to second-line drugs necessitates precise diagnostic testing for effective treatment.

Purpose of the Study:

• To provide comprehensive management guidance for optimizing MDR-TB diagnosis and treatment.
• To highlight the role of novel oral drugs, such as bedaquiline, in creating personalized MDR-TB regimens.
• To discuss adjunctive therapies including surgery, physiotherapy, rehabilitation, palliative care, and smoking cessation.

Main Methods:

• Review of current literature and clinical guidelines for MDR-TB management.
• Emphasis on genotypic and phenotypic drug susceptibility testing for personalized treatment.
• Integration of novel drug therapies and supportive care strategies.

Main Results:

• Novel oral drugs enable the design of potent, well-tolerated, and personalized MDR-TB treatment regimens.
• Optimized diagnosis, algorithm-based treatment, and therapeutic drug monitoring are crucial.
• Management of adverse events, comorbidities, and the incorporation of supportive care improve outcomes.

Conclusions:

• Personalized treatment regimens, including novel oral drugs, are essential for improving MDR-TB outcomes.
• A multidisciplinary approach encompassing medical, surgical, and supportive care enhances treatment success.
• Implementing these recommendations can lead to higher relapse-free cure rates for MDR-TB patients.